Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT) : a multicentre, randomised, placebo-controlled, phase 3 trial

Source
The lancet neurology - ISSN 1474-4422-20:7 (2021) p. 526-536
Author(s)
    James F. Howard, Vera Bril, Tuan Vu, Chafic Karam, Stojan Peric, Temur Margania, Hiroyuki Murai, Malgorzata Bilinska, Roman Shakarishvili, Marek Smilowski, Antonio Guglietta, Peter Ulrichts, Tony Vangeneugden, Kimiaki Utsugisawa, Jan Verschuuren, Renato Mantegazza, Jan L. De Bleecker, Kathy De Koning, Katrien De Mey, Annelien De Pue, Rudolf Mercelis, Maren Wyckmans, Caroline Vinck, Linda Wagemaekers, Jonathan Baets, Eduardo Ng, Jafar Shabanpour, Lubna Daniyal, Shabber Mannan, Hans D. Katzberg, Angela Genge, Zaeem Siddiqi, Jana Junkerová, Jana Horakova, Katerina Reguliova, Michaela Tyblova, Ivana Jurajdova, Iveta Novakova, Michala Jakubikova, Jiri Pitha, Stanislav Vohanka, Katerina Havelkova, Tomas Horak, Josef Bednarik, Mageda Horakova, Andreas Meisel, Dike Remstedt, Claudia Heibutzki, Siegfried Kohler, Benjamin Frishberg